Cargando…

Treatment-related adverse events and response rate to immune checkpoint inhibition

BACKGROUND: Immune checkpoint inhibition (ICI) represents a novel treatment modality for refractory cancers, and improving prediction of potential responders is critical. METHOD: We hypothesized that ICI is a systemic-effecting mechanism. The objective response rate (ORR) for anti-PD-1, anti-PD-L1,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yanmin, Wang, Zhengping, Guo, Ting, Liu, Shenghua, Feng, Chenchen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Clinical Research Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783260/ https://www.ncbi.nlm.nih.gov/pubmed/31777292 http://dx.doi.org/10.1177/0300060519886454

Ejemplares similares

Management of immune checkpoint inhibitor‐related dermatologic adverse events
por: Si, Xiaoyan, et al.
Publicado: (2019)

Management of immune checkpoint inhibitor‐related rheumatic adverse events
por: Zhou, Jiaxin, et al.
Publicado: (2019)

Treatment-related adverse events as surrogate to response rate to immune checkpoint blockade
por: Shen, Yanyun, et al.
Publicado: (2020)

Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor‐related hematological adverse events
por: Zhuang, Junling, et al.
Publicado: (2020)

Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition
por: Ghosh, Nilasha, et al.
Publicado: (2022)

Clinical recommendations on diagnosis and treatment of immune checkpoint inhibitor‐induced renal immune‐related adverse events
por: Zheng, Ke, et al.
Publicado: (2020)

Biomarkers, Clinical Features, and Rechallenge for Immune Checkpoint Inhibitor Renal Immune-Related Adverse Events
por: Isik, Busra, et al.
Publicado: (2021)

Endocrine‐related adverse events associated with immune‐checkpoint inhibitors in patients with melanoma
por: Kassi, Eva, et al.
Publicado: (2019)

External validation of biomarkers for immune-related adverse events after immune checkpoint inhibition
por: Glehr, Gunther, et al.
Publicado: (2022)

Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance
por: Verheijden, Rik J., et al.
Publicado: (2023)

The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors
por: Jia, Xiao-Hui, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events
por: Herrmann, Sandra M., et al.
Publicado: (2020)

Cardiac Adverse Events Related to Immune Checkpoint Inhibitors
por: Gujral, Dorothy M., et al.
Publicado: (2020)

Management of adverse events related to checkpoint inhibition therapy
por: Rudzki, Jakob Daniel
Publicado: (2018)

Alopecia areata as an immune-related adverse event associated with response to immune checkpoint inhibitors
por: Suzuki, Rika, et al.
Publicado: (2023)

The effects of B cell depletion on immune related adverse events associated with immune checkpoint inhibition
por: Risbjerg, Rasmus Strøm, et al.
Publicado: (2020)

The Role of Cytokines in Predicting the Response and Adverse Events Related to Immune Checkpoint Inhibitors
por: Wang, Min, et al.
Publicado: (2021)

Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors
por: Choi, Juwhan, et al.
Publicado: (2020)

Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors
por: Xiao, Yan, et al.
Publicado: (2020)

Rheumatic immune‐related adverse events induced by immune checkpoint inhibitors
por: Zhong, Hui, et al.
Publicado: (2020)

Ophthalmic immune-related adverse events associated with immune checkpoint inhibitors
por: Gan, Linyang, et al.
Publicado: (2023)

Immune-related adverse events of immune checkpoint inhibitors: a review
por: Yin, Qinan, et al.
Publicado: (2023)

Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events
por: Siddiqui, Bilal A, et al.
Publicado: (2021)

Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events
por: Poto, Remo, et al.
Publicado: (2022)

Thyroid-related adverse events induced by immune checkpoint inhibitors
por: Chera, Alexandra, et al.
Publicado: (2022)

Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events
por: Les, Iñigo, et al.
Publicado: (2023)

Insights Into the Host Contribution of Endocrine Associated Immune-Related Adverse Events to Immune Checkpoint Inhibition Therapy
por: Chye, Adrian, et al.
Publicado: (2022)

Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors
por: Weinmann, Sophia C, et al.
Publicado: (2019)

Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer
por: Shao, Jun, et al.
Publicado: (2020)

Immune-related adverse events in the treatment of non-Hodgkin lymphoma with immune checkpoint inhibitors
por: Argnani, Lisa, et al.
Publicado: (2022)

Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition
por: Henderson Berg, Meagan-Helen, et al.
Publicado: (2022)

Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors
por: Dolladille, Charles, et al.
Publicado: (2020)

Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
por: Das, Satya, et al.
Publicado: (2019)

Equibalancing immune‐related adverse events and anticancer activity of immune checkpoint inhibitors
por: Seeruttun, Sharvesh Raj
Publicado: (2019)

Ocular adverse events with immune checkpoint inhibitors
por: Fang, Tony, et al.
Publicado: (2019)

Mucocutaneous adverse events to immune checkpoint inhibitors
por: Muhaj, Fiorinda, et al.
Publicado: (2023)

Unexpected Adverse Events of Immune Checkpoint Inhibitors
por: Shalata, Walid, et al.
Publicado: (2023)

Landscape of immune checkpoint inhibitor-related adverse events in Chinese population
por: Li, Li, et al.
Publicado: (2020)

Mechanisms and Management of Immune Checkpoint Inhibitor-Related Cardiac Adverse Events
por: Kadowaki, Hiroshi, et al.
Publicado: (2021)

Steroid-Refractory Immune-Related Adverse Events Induced by Checkpoint Inhibitors
por: Tomsitz, Dirk, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ibrh0cv2jan7mh8kv7etquhqih